Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma | Zendy

Seunggu J. Han | Zendy; John D. Rolston | Zendy; Annette M. Molinaro | Zendy; Jennifer Clarke | Zendy; Michael D. Prados | Zendy; Shan Chang | Zendy; Mitchel S. Berger | Zendy; Annissa DeSilva | Zendy; Nicholas Butowski | Zendy

AI Assistant Blog Pricing

Open Access

Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma

Author(s) -

Seunggu J. Han,

John D. Rolston,

Annette M. Molinaro,

Jennifer Clarke,

Michael D. Prados,

Shan Chang,

Mitchel S. Berger,

Annissa DeSilva,

Nicholas Butowski

Publication year - 2014

Publication title -

neuro-oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.005

H-Index - 125

eISSN - 1523-5866

pISSN - 1522-8517

DOI - 10.1093/neuonc/nou044

Subject(s) - temozolomide , medicine , bevacizumab , clinical endpoint , regimen , glioma , progression free survival , phases of clinical research , log rank test , gastroenterology , surgery , chemotherapy , clinical trial , survival analysis , cancer research

A phase II trial was performed to evaluate the efficacy of a dose-dense, 7 days on/7 days off schedule of temozolomide for patients with recurrent high-grade gliomas (HGG).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog